Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab.
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antiviral Agents
/ therapeutic use
COVID-19
/ diagnosis
Drug Therapy, Combination
/ methods
Female
Graft Rejection
/ immunology
Heparin, Low-Molecular-Weight
/ therapeutic use
Humans
Hydroxychloroquine
/ therapeutic use
Immunosuppression Therapy
/ adverse effects
Immunosuppressive Agents
/ adverse effects
Kidney Transplantation
/ adverse effects
Lopinavir
/ therapeutic use
Lung
/ diagnostic imaging
Middle Aged
Prednisolone
/ therapeutic use
Respiration, Artificial
Ritonavir
/ therapeutic use
SARS-CoV-2
/ immunology
Severity of Illness Index
Tomography, X-Ray Computed
Treatment Outcome
COVID-19
coronavirus
immunosuppression
kidney transplantation
pandemic
tocilizumab
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
25
04
2020
revised:
07
05
2020
accepted:
15
05
2020
pubmed:
26
5
2020
medline:
16
12
2020
entrez:
26
5
2020
Statut:
ppublish
Résumé
Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.
Identifiants
pubmed: 32449235
doi: 10.1111/tid.13334
pmc: PMC7267155
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antiviral Agents
0
Heparin, Low-Molecular-Weight
0
Immunosuppressive Agents
0
Lopinavir
2494G1JF75
Hydroxychloroquine
4QWG6N8QKH
Prednisolone
9PHQ9Y1OLM
tocilizumab
I031V2H011
Ritonavir
O3J8G9O825
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13334Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Infez Med. 2020 Ahead of print Jun 1;28(2):143-152
pubmed: 32275256
Am J Transplant. 2020 Jul;20(7):1941-1943
pubmed: 32233067
Transplantation. 2011 Aug 27;92(4):396-403
pubmed: 21818055
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Cochrane Database Syst Rev. 2019 Feb 24;2:CD010406
pubmed: 30798570
Am J Transplant. 2020 Jul;20(7):1875-1878
pubmed: 32198834
Transpl Infect Dis. 2020 Aug;22(4):e13296
pubmed: 32301198
Am J Transplant. 2020 Jul;20(7):1944-1946
pubmed: 32282977
Lancet Infect Dis. 2010 Aug;10(8):521-6
pubmed: 20620116
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Transpl Infect Dis. 2020 Oct;22(5):e13334
pubmed: 32449235
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Transpl Infect Dis. 2020 Aug;22(4):e13286
pubmed: 32279418
Am J Transplant. 2020 Jul;20(7):1902-1906
pubmed: 32324331
Front Immunol. 2019 Dec 19;10:2978
pubmed: 31921213
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
Am J Transplant. 2020 Jul;20(7):1859-1863
pubmed: 32181990
N Engl J Med. 2006 Apr 27;354(17):1775-86
pubmed: 16641394
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Transpl Int. 2020 Jul;33(7):824-825
pubmed: 32236983
J Heart Lung Transplant. 2020 May;39(5):408-409
pubmed: 32253113
Am J Transplant. 2020 Jul;20(7):1809-1818
pubmed: 32282982
Ecancermedicalscience. 2020 Mar 27;14:1022
pubmed: 32256705
Am J Transplant. 2020 Jul;20(7):1882-1884
pubmed: 32243672